Mirati Therapeutics ticks higher amid Nasdaq delisting for sale to Bristol-Myers

seekingalpha01-20

Mirati Therapeutics (NASDAQ:MRTX) ticked up 0.3% amid a Nasdaq de-listing notice for its planned $4.8 billion sale to Bristol-Myers Squibb (NYSE:BMY). The deal is tentatively scheduled to close on Jan...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2404687547?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1324669080/image_1324669080.jpg","is_english":true,"pubTime":"2024-01-20 02:24","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2404687547","market":"us","top_or_hot":-1,"title":"Mirati Therapeutics ticks higher amid Nasdaq delisting for sale to Bristol-Myers","media":"seekingalpha","content":"<div>\n<p>Mirati Therapeutics (NASDAQ:MRTX) ticked up 0.3% amid a Nasdaq de-listing notice for its planned $4.8 billion sale to Bristol-Myers Squibb (NYSE:BMY). The deal is tentatively scheduled to close on Jan...</p>\n\n<a href=\"https://seekingalpha.com/news/4056557-mirati-therapeutics-ticks-higher-amid-nasdaq-delisting-for-sale-to-bristol-myers\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mirati Therapeutics ticks higher amid Nasdaq delisting for sale to Bristol-Myers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMirati Therapeutics ticks higher amid Nasdaq delisting for sale to Bristol-Myers\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-01-20 02:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4056557-mirati-therapeutics-ticks-higher-amid-nasdaq-delisting-for-sale-to-bristol-myers><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Mirati Therapeutics (NASDAQ:MRTX) ticked up 0.3% amid a Nasdaq de-listing notice for its planned $4.8 billion sale to Bristol-Myers Squibb (NYSE:BMY). The deal is tentatively scheduled to close on Jan...</p>\n\n<a href=\"https://seekingalpha.com/news/4056557-mirati-therapeutics-ticks-higher-amid-nasdaq-delisting-for-sale-to-bristol-myers\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2125154935.USD","symbol_name":"ALLSPRING (LUX) WF GLOBAL EQUITY ENHANCED INCOME \"I\" (USD) INC","start_time":0,"source_url":"https://seekingalpha.com/news/4056557-mirati-therapeutics-ticks-higher-amid-nasdaq-delisting-for-sale-to-bristol-myers","article_id":"2404687547","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1324669080/image_1324669080.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2404687547","pubTimestamp":1705688662,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Mirati Therapeutics  ticked up 0.3% amid a Nasdaq de-listing notice for its planned $4.8 billion sale to Bristol-Myers Squibb . The deal is tentatively scheduled to close on Jan. 23, according to the Nasdaq notice. The stock will be halted at 8pm on Jan. 22.  Bristol-Myers  in October agreed to purchase Mirati  for $58 in cash plus a $12 share contingent value right.     More on Mirati Therapeutics  Evaluating Mirati Therapeutics' CVR Value In The Wake Of The Bristol Myers Acquisition Mirati's Krazati gets EU conditional approval for lung cancer Mirati Therapeutics gains as HSR waiting period for sale to Bristol-Myers expires Seeking Alpha’s Quant Rating on Mirati Therapeutics Historical earnings data for Mirati Therapeutics","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2125154935.USD":"ALLSPRING (LUX) WF GLOBAL EQUITY ENHANCED INCOME \"I\" (USD) INC",".IXIC":"NASDAQ Composite","BK4126":"金属与玻璃容器","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU1032466523.USD":"高盛全球多资产收益组合Acc","BK4532":"文艺复兴科技持仓","LU0882574055.USD":"富达全球健康医疗A ACC","MRTX":"Mirati Therapeutics Inc.","LU1670711040.USD":"M&G (LUX) GLOBAL DIVIDEND \"A\" (USD) ACC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4585":"ETF&股票定投概念","QQQ":"纳指100ETF","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","BK4007":"制药","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","SQQQ":"纳指三倍做空ETF","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","QLD":"纳指两倍做多ETF","BMY":"施贵宝","QID":"纳指两倍做空ETF","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","BK4588":"碎股","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","TQQQ":"纳指三倍做多ETF","MYE":"Myers Industries Inc","LU2242646821.SGD":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD","PSQ":"纳指反向ETF","LU2360032135.SGD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (SGDHDG) INC","LU0237698245.USD":"富达环球地产基金A","LU2125154778.USD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (USD) INC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","BK4581":"高盛持仓","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU1261432733.SGD":"Fidelity World A-ACC-SGD","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC"},"translate_title":"Mirati Therapeutics股价上涨，纳斯达克退市出售给百时美施贵宝","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{".IXIC":1,"MYE":1,"MRTX":1,"BMY":1,"PSQ":0.6,"QID":0.6,"QLD":0.6,"QQQ":0.6,"SQQQ":0.6,"TQQQ":0.6,"MNQmain":0.6,"NQmain":0.6},"content_text":"Mirati Therapeutics (NASDAQ:MRTX) ticked up 0.3% amid a Nasdaq de-listing notice for its planned $4.8 billion sale to Bristol-Myers Squibb (NYSE:BMY). The deal is tentatively scheduled to close on Jan. 23, according to the Nasdaq notice. The stock will be halted at 8pm on Jan. 22.  Bristol-Myers (BMY) in October agreed to purchase Mirati (MRTX) for $58 in cash plus a $12 share contingent value right.     More on Mirati Therapeutics  Evaluating Mirati Therapeutics' CVR Value In The Wake Of The Bristol Myers Acquisition Mirati's Krazati gets EU conditional approval for lung cancer Mirati Therapeutics gains as HSR waiting period for sale to Bristol-Myers expires Seeking Alpha’s Quant Rating on Mirati Therapeutics Historical earnings data for Mirati Therapeutics","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2404687547"}